NCT06657846 HRQoL and Financial Toxicity in Patients With VEXAS Syndrome
| NCT ID | NCT06657846 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Condition | VEXAS |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2025-06-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-11-01 with a primary completion date of 2025-06-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter cross-sectional observational study aims to describe health-related quality of life (HRQoL) and symptom profiles of patients with VEXAS syndrome.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥ 18 years old) with a confirmed diagnosis of VEXAS syndrome (UBA1 pathogenic mutation detected) * Written informed consent Exclusion Criteria: * \- Having any kind of psychiatric disorder or major cognitive dysfunction. * Not able to read and understand local language
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06657846 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying VEXAS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06657846 currently recruiting?
Yes, NCT06657846 is actively recruiting participants. Contact the research team at f.efficace@gimema.it for enrollment information.
Where is the NCT06657846 trial being conducted?
This trial is being conducted at Ancona, Italy, Bergamo, Italy, Bologna, Italy, Brescia, Italy and 11 additional locations.
Who is sponsoring the NCT06657846 clinical trial?
NCT06657846 is sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto. The trial plans to enroll 100 participants.